Home / Academia / Pluristem’s PLX Stem Cells Protect Neurons Depleted of Oxygen
Image Credit: Pixabay

Pluristem’s PLX Stem Cells Protect Neurons Depleted of Oxygen פלוריסטם הודיעה כי מחקר בתאי השלייה של החברה התקבל לפרסום

Pluristem Therapeutics Inc. (Nasdaq:PSTI, TASE:PSTI) announced that a study of its PLacental eXpanded (PLX) cells was accepted for publication in the February 2015 issue of Biochimica et Biophysica Acta Molecular Cell Research. The study shows that PLX cells protect various nerve cells from death after oxygen and glucose deprivation. The protective effects of PLX cells were strongly correlated with the secretion of interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF), which are known to have neuroprotective effects in humans with injuries to the nervous system that can occur after events such as a stroke.

“Our findings suggest that PLX cells may potentially treat damaged nerves, and may corroborate and explain the mechanism that leads to one of our findings in our Phase I trial in critical limb ischemia. In that study, patients treated with PLX cells had a statistically significant reduction in pain as compared to their baseline. An earlier preclinical study, published in the journal Brain Research, showed that PLX cells may effectively treat ischemic stroke,” stated Pluristem CEO Zami Aberman.

Aberman continued, “These latest findings also call to mind two earlier preclinical studies, which indicated that PLX cells may be an effective treatment for both neuropathic and inflammatory nerve pain, suggesting that PLX cells could be a potential treatment for chronic nerve pain resulting from conditions such as diabetic neuropathy.”

The study was conducted jointly by researchers at Pluristem and Prof. Philip Lazarovici, Jacob Gitlin Chair in Physiology and Pharmacology at the School of Pharmacy Institute for Drug Research at the Hebrew University and co-authored by Prof. Ephraim Yavin of the Department of Neurobiology at the Weizmann Institute of Science. The study was supported by the Magnet Program of Israel’s Ministry of Economy.

About Pluristem Therapeutics

Based in Haifa, Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company’s patented PLX (PLacental eXpanded) cells release a cocktail of therapeutic proteins in response to inflammation, hematological disorders, radiation damage, and ischemia. PLX cells are grown using the Company’s proprietary three-dimensional expansion technology and are an “off-the-shelf” product that requires no tissue matching prior to administration.



About bio972

Leave a Reply